Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run

Bristol-Myers Squibb has delivered a strong 38.1% share price gain over the past year, even as shorter term moves have been weaker. This naturally raises the question of whether that climb is fully supported by the earnings the business is generating today. That 38.1% one year return puts more weight on the question of whether the current valuation is still in line with what Bristol-Myers Squibb actually earns. Fresh positive late stage trial results across cancer, cardiology and respiratory...